精氨酸酶
化学
鸟氨酸
精氨酸
免疫系统
酶
硼酸
生物化学
免疫疗法
尿素循环
氨基酸
癌症研究
组合化学
免疫学
生物
作者
Bartłomiej Borek,Tadeusz Gajda,Adam Gołębiowski,Roman Błaszczyk
标识
DOI:10.1016/j.bmc.2020.115658
摘要
Arginase is an enzyme that converts l-arginine to l-ornithine and urea in the urea cycle. There are two isoforms of arginase in mammals: ARG-1 and ARG-2. l-Arginine level changes occur in patients with various types of affliction. An overexpression of arginase leads to the depletion of arginine and then to inhibition of the growth of T and NK cells, and in effect to the tumor escape of the immune response. Based on those observations, an inhibition of arginase is proposed as a method to improve anti-tumor immune responses (via an activation and proliferation of T and NK cells). Boronic acid derivatives as arginase inhibitors are leading, potential therapeutic agents for the treatment of several diseases. All these compounds are derived from the original 2-(S)-amino-6-boronohexanoic acid (ABH), the first boronic acid arginase inhibitor proposed by Christianson et al. This article focuses on the review of such sub-class of arginase inhibitors and highlights their SAR and PK properties. It covers molecules published until early 2020, including patent applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI